Age: 78.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Purpura, Rash, Sjogren's syndrome, Superficial inflammatory dermatosis, Tremor
Clinical narrative: Parotiditis; allergic to it; lymphocytic dermatitis; lymphocytic dermatitis with purpura; tremors; major discomfort occurred; Rash Increased; Increased Sjogren's; Increased Sjogren's; The initial safety information received was reporting only non-serious adverse drug reaction(s), Upon receipt of follow-up information on [10Apr2023], this case now contains serious adverse reaction(s). Information processed together.  This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  An 80-year-old female patient received BNT162b2 (BNT162B2), on 18Mar2021 as dose 2, single (Lot number: EN6204) at the age of 78 years intramuscular, in right arm for covid-19 immunisation. The patient's relevant medical history included: "Scleroderma", start date: 1993 (unspecified if ongoing); "Hashimoto's thyroiditis" (unspecified if ongoing); "Thyroidectomy" (unspecified if ongoing); "Colectomy", start date: 2003 (unspecified if ongoing), notes: bladder; "Fistula" (unspecified if ongoing); "Vasculitis" (unspecified if ongoing), notes: Morphology: Palpable purpura with necrotic centers; DDX: Vasculitis; "Sjogren's syndrome" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: pfizer biontech covid 19 vaccine (dose 1, single, right arm, intramuscular, Lot number: EN6202), administration date: 26Feb2021, when the patient was 78-year-old, for covid-19 immunisation, reaction(s): "increased Sjogren's"; pfizer biontech covid-19 vaccine (dose 1, single, right arm, intramuscular, Lot number: EN6202), administration date: 26Feb2021, when the patient was 78-year-old, for covid-19 immunisation, reaction(s): "increased Sjogren's", "rash". The following information was reported: SJOGREN'S SYNDROME (medically significant), CONDITION AGGRAVATED (medically significant) all with onset 19Mar2021, outcome "unknown" and all described as "Increased Sjogren's"; RASH (non-serious) with onset 19Mar2021, outcome "unknown", described as "Rash Increased"; PAROTITIS (medically significant), outcome "unknown", described as "Parotiditis"; DRUG HYPERSENSITIVITY (non-serious), outcome "unknown", described as "allergic to it"; SUPERFICIAL INFLAMMATORY DERMATOSIS (non-serious), outcome "unknown", described as "lymphocytic dermatitis"; PURPURA (non-serious), outcome "unknown", described as "lymphocytic dermatitis with purpura"; TREMOR (non-serious), outcome "unknown", described as "tremors"; DISCOMFORT (non-serious), outcome "unknown", described as "major discomfort occurred". The events "increased sjogren's" and "rash increased" required physician office visit. Reaction to MRNA vaccine and now declared allergic to it. Want info and contact with a researcher on this issue.Patient asking what can be done for lymphocytic dermatitis with purpura and if others experienced this adverse event after vaccination. Patient reports experiencing tremors and lymphocytic dermatitis with purpura after receiving the COVID-19 vaccine more than one year ago. After each dose, Sjogren's worsened to the point of significant loss of body fluid in all gland areas. Parotiditis, salivary gland removal, and major discomfort occurred.The rash appeared after initial dose and increased after each dose. Doctors kept telling me it was telangiectasias but I knew it was something else. Rheumatologist ref. me to medical dermatologist where biopsy was done. Treated with Rutin, Hight Vitamin C and cream. Continued to worsen and finished methoprednisolone pack 6 weeks ago. That helped but leg scarring is not going away.Final Diagnosis:Skin, left proximal pretibial region- Perivascular lymphocytic dermatitis with purpura. Similar morphological changes can be seen within the spectrum of findings present in pigmented purpuric dermatosis, which is favored in this biopsy. While an evolving lesion of leukocytoclastic vasculitis cannot be entirely excluded, diagnostic features are not observed in multiple level sections examined. The patient underwent the following laboratory tests and procedures: Biopsy: pigmented purpuric dermatosis, notes: Similar morphological changes can be seen within the spectrum of findings present in pigmented purpuric dermatosis, which is favored in this biopsy. While an evolving lesion of leukocytoclastic vasculitis cannot be entirely excluded, diagnostic features are not observed in multiple level sections examined. Therapeutic measures were taken as a result of sjogren's syndrome, condition aggravated, parotitis, rash.; Sender's Comments: Linked Report(s) : US-PFIZER INC-PV202300016867 same patient, different drug/event;